Wednesday, July 22, 2026

North Korea’s Kim Yo-jong Declares Denuclearization Impossible: What This Means for Asia

South Korea reiterates commitment to denuclearization amid North Korea's rejection, emphasizing international cooperation and safety.

U.S. Strategy Shift: How North Korea Gains Strategic Leverage Amid Military Rivalry

U.S. strategy shifts may fuel an arms race, empowering North Korea's influence and complicating security dynamics in the region.

Breakthrough Cancer Drug BAL0891: Key Findings to be Revealed at AACR 2026

SillaJen's cancer drug BAL0891 will be presented at the AACR 2026 conference, highlighting its effects on gastric and breast cancer models.

Tag: ADC

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.